Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UCLA Presents Data on Medicinova Inc's MN-166 in Methamphetamine Addiction


Tuesday, 18 Jun 2013 07:00pm EDT 

Medicinova Inc announced the presentation of preliminary results from a Phase 1b study of MN-166 (ibudilast) in methamphetamine addiction. Preliminary results from one cognitive performance task, presented in a poster session, showed significant improvement in measures of sustained attention in subjects completing a treatment sequence ending with a one-week course of MN-166 dosing at 100 mg/day versus those subjects completing the treatment sequence on an inactive control (placebo). Analyses showed that in the presence of relevant doses of methamphetamine, MN-166 produced no significant changes in blood pressure or heart rate. A Phase 2 outpatient clinical trial of MN-166 in methamphetamine dependence, led by investigators at University of California at Los Angeles (UCLA), has been funded by National Institute on Drug Abuse (NIDA). 

Company Quote

224.0
3.0 +1.36%
20 Aug 2014